Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

$4.14 -0.03 (-0.72 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$4.17
Today's Range$4.08 - $4.56
52-Week Range$2.40 - $5.68
Volume1.07 million shs
Average Volume284,540 shs
Market Capitalization$173.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Debt-to-Equity Ratio0.32%
Current Ratio7.21%
Quick Ratio7.21%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.40 million
Price / Sales39.23
Cash FlowN/A
Price / CashN/A
Book Value$1.77 per share
Price / Book2.34

Profitability

Trailing EPS($0.94)
Net Income$-33,460,000.00
Net Margins-935.09%
Return on Equity-64.55%
Return on Assets-46.97%

Miscellaneous

Employees66
Outstanding Shares41,690,000

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The firm's revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.

Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?

6 equities research analysts have issued twelve-month price targets for Fate Therapeutics' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Fate Therapeutics' share price to reach $7.20 in the next year. View Analyst Ratings for Fate Therapeutics.

What are Wall Street analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:

  • 1. HC Wainwright analysts commented, "Early Encouraging Data With FATE-NK 100 in r/r AML at SITC Significant reductions of leukemic blasts observed in two patients. This morning, Fate reported initial clinical data from the ongoing VOYAGE Phase 1 study, which is investigating FATE-NK100 as a monotherapy for the treatment of r/r acute myelogenous leukemia (AML). After a single dose of FATE-NK100, we note that a subject in the second dose cohort (2×10 7 cells/kg) achieved a morphologic leukemia-free state (mLFS). At day 14, a bone marrow biopsy indicated total clearance of leukemic blasts in the marrow. A second patient from the first dose cohort of VOYAGE (1×10 7 cells/kg) had approximately 50% reduction in leukemic blasts. This patient had a tremendous high disease burden (87% blasts in the marrow). The patient that had the total clearance of leukemic blasts in the marrow had approximately 3×10 4 FATE-NK100 cells per mL in the peripheral blood at day 14 following treatment. In the other patient, after two weeks, approximately 76% of NK cells in the peripheral blood were of FATE-NK100 origin. We view these results as promising and look forward to additional data at higher doses as no dose limiting toxicities (DLTs) were reported so far. The next dose cohort is 1×10 8 cells/kg. In the trial, we note that FATE-NK100 cells persisted in both subjects for at least 14 days with a single dose. We believe this will play an important role for upcoming studies where Fate plans to investigate the combination of FATE-NK100 in advanced solid tumors with monoclonal antibody therapy." (11/10/2017)
  • 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (10/17/2017)
  • 3. BMO Capital Markets analysts commented, "We are raising our price target to $7 from $4, following 4Q16 earnings that underlined growing interesting in Fate's earlier stage assets, NK100 and iPSC. Our DCF valuation increases as we assign value for these therapies to continue revenue growth beyond ProTmune. We expect ProTmune Phase I interim data in mid-2017 and NK100 to enroll its first AML patient in 2Q17. Fate's hnCD16-iNK could start human trials by early 2018. While we see tremendous potential in the NK100 and iPSC platforms, we wait for clinical validation before including them in our model." (3/17/2017)

Who are some of Fate Therapeutics' key competitors?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
  • J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director (Age 44)
  • John D. Mendlein Ph.D., Vice Chairman of the Board (Age 57)
  • Jim Beitel, Senior Vice President - Corporate Development
  • Daniel D. Shoemaker Ph.D., Chief Scientific Officer (Age 47)
  • John Ferraro, Vice President - Clinical Operations
  • Wendy Levin, Vice President - Clinical Development
  • Walter Grubb, Vice President - Business Development
  • Cindy Tahl J.D., General Counsel
  • Stewart Abbot Ph.D., Chief Development Officer

Who owns Fate Therapeutics stock?

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include 683 Capital Management LLC (1.63%), Neuberger Berman Group LLC (0.32%), Victory Capital Management Inc. (0.22%), OxFORD Asset Management LLP (0.19%), Algert Global LLC (0.17%) and Russell Investments Group Ltd. (0.14%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC and OxFORD Asset Management LLP. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.

Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?

Fate Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., 683 Capital Management LLC, Neuberger Berman Group LLC, Russell Investments Group Ltd. and Hochman Cole Investment Advisors Inc.. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

How do I buy Fate Therapeutics stock?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of Fate Therapeutics stock can currently be purchased for approximately $4.14.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $173.83 million and generates $4.40 million in revenue each year. The biopharmaceutical company earns $-33,460,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Fate Therapeutics employs 66 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (FATE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.20$7.20$7.00$6.40
Price Target Upside: 73.91% upside65.52% upside67.06% upside55.72% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Price Target History for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy$7.00N/AView Rating Details
11/2/2017BMO Capital MarketsReiterated RatingBuy$7.00N/AView Rating Details
9/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$7.00MediumView Rating Details
5/16/2017WedbushReiterated RatingOutperform$7.00HighView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
5/10/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Fate Therapeutics (NASDAQ:FATE) Earnings History and Estimates Chart

Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ FATE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.25)($0.26)$0.95 million$1.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)$1.02 million$1.03 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.21)($0.24)$1.04 million$1.03 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.28)($0.21)$1.06 million$1.03 millionViewN/AView Earnings Details
11/7/2016Q316($0.29)($0.27)$1.05 million$1.03 millionViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)$0.84 million$1.32 millionViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$0.58 million$1.08 millionViewN/AView Earnings Details
11/3/2015Q315($0.32)($0.24)$0.46 million$1.03 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
5/7/2015Q115($0.34)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014Q3 2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Fate Therapeutics (NASDAQ:FATE) Earnings Estimates

2017 EPS Consensus Estimate: ($0.98)
2018 EPS Consensus Estimate: ($1.02)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.22)($0.23)
Q2 20172($0.25)($0.24)($0.25)
Q3 20172($0.25)($0.24)($0.25)
Q4 20172($0.26)($0.25)($0.26)
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.28)($0.28)($0.28)
Q4 20181($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.88%
Institutional Ownership Percentage: 60.97%
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ FATE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Cindy TahlGeneral CounselSell8,091$3.85$31,150.35View SEC Filing  
10/16/2017Daniel D ShoemakerInsiderSell13,225$3.87$51,180.75View SEC Filing  
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.38View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fate Therapeutics (NASDAQ FATE) News Headlines

Source:
DateHeadline
Fate Therapeutics (FATE) Buy Rating Reiterated at Raymond James FinancialFate Therapeutics' (FATE) Buy Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 12 at 12:46 PM
Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 StageFate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage
finance.yahoo.com - December 12 at 9:59 AM
Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered ... - StreetInsider.comFate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered ... - StreetInsider.com
www.streetinsider.com - December 11 at 5:29 PM
Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling ... - GlobeNewswire (press release)Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 5:29 PM
Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered Master Pluripotent Cell LineFate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered Master Pluripotent Cell Line
www.streetinsider.com - December 11 at 10:17 AM
Fate Therapeutics, Inc. (FATE) Given Average Rating of "Buy" by AnalystsFate Therapeutics, Inc. (FATE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 10 at 1:52 AM
Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell ImmunotherapyFate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy
finance.yahoo.com - December 9 at 5:10 PM
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian CancerFate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer
finance.yahoo.com - December 8 at 5:10 PM
Zacks: Brokerages Expect Fate Therapeutics, Inc. (FATE) Will Announce Quarterly Sales of $1.02 MillionZacks: Brokerages Expect Fate Therapeutics, Inc. (FATE) Will Announce Quarterly Sales of $1.02 Million
www.americanbankingnews.com - December 8 at 6:32 AM
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? - NasdaqAre Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? - Nasdaq
www.nasdaq.com - December 6 at 5:18 PM
Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer ImmunotherapiesFate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies
finance.yahoo.com - December 6 at 9:42 AM
ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVVASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV
www.rttnews.com - December 5 at 10:15 AM
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
finance.yahoo.com - December 5 at 10:15 AM
ValuEngine Lowers Fate Therapeutics (FATE) to SellValuEngine Lowers Fate Therapeutics (FATE) to Sell
www.americanbankingnews.com - December 3 at 3:12 PM
 Analysts Expect Fate Therapeutics, Inc. (FATE) Will Post Quarterly Sales of $1.02 Million Analysts Expect Fate Therapeutics, Inc. (FATE) Will Post Quarterly Sales of $1.02 Million
www.americanbankingnews.com - November 20 at 9:04 AM
ETFs with exposure to Fate Therapeutics, Inc. : November 17, 2017ETFs with exposure to Fate Therapeutics, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 12:12 PM
Boston Childrens reverses type 1 diabetes in miceBoston Children's reverses type 1 diabetes in mice
finance.yahoo.com - November 16 at 2:10 PM
Fate Therapeutics, Inc. (FATE) Given Average Recommendation of "Buy" by BrokeragesFate Therapeutics, Inc. (FATE) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 15 at 1:46 AM
Fate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML at SITCFate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML at SITC
www.streetinsider.com - November 10 at 7:48 PM
BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100
www.reuters.com - November 10 at 7:48 PM
HC Wainwright Reaffirms "Buy" Rating for Fate Therapeutics, Inc. (FATE)HC Wainwright Reaffirms "Buy" Rating for Fate Therapeutics, Inc. (FATE)
www.americanbankingnews.com - November 10 at 2:48 PM
Fate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML ... - StreetInsider.comFate Therapeutics (FATE) Announces Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for R/R AML ... - StreetInsider.com
www.streetinsider.com - November 10 at 2:44 PM
Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual MeetingFate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting
finance.yahoo.com - November 10 at 2:44 PM
ETFs with exposure to Fate Therapeutics, Inc. : November 6, 2017ETFs with exposure to Fate Therapeutics, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 8:17 PM
Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 12:29 PM
Fate Therapeutics (FATE) CEO Scott Wolchko on Q3 2017 Results ... - Seeking AlphaFate Therapeutics' (FATE) CEO Scott Wolchko on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - November 2 at 7:49 PM
Fate Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Fate Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 2 at 7:49 PM
Fate Therapeutics, Inc. (FATE) Issues  Earnings ResultsFate Therapeutics, Inc. (FATE) Issues Earnings Results
www.americanbankingnews.com - November 2 at 3:06 PM
Fate Therapeutics Announces Six Presentations at the 2017 ASH Annual MeetingFate Therapeutics Announces Six Presentations at the 2017 ASH Annual Meeting
finance.yahoo.com - November 1 at 7:41 PM
Fate Therapeutics, Inc. to Host Earnings CallFate Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 7:41 PM
Fate Therapeutics Reports Third Quarter 2017 Financial ResultsFate Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 7:41 PM
Fate Therapeutics reports 3Q lossFate Therapeutics reports 3Q loss
finance.yahoo.com - November 1 at 7:41 PM
Fate Therapeutics, Inc. (FATE) Expected to Post Quarterly Sales of $1.02 MillionFate Therapeutics, Inc. (FATE) Expected to Post Quarterly Sales of $1.02 Million
www.americanbankingnews.com - October 31 at 9:00 AM
Fate Therapeutics, Inc. (FATE) to Release Earnings on MondayFate Therapeutics, Inc. (FATE) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 9:15 AM
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial ResultsFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results
finance.yahoo.com - October 25 at 9:00 PM
Fate Therapeutics (FATE) & Its Peers Critical ReviewFate Therapeutics (FATE) & Its Peers Critical Review
www.americanbankingnews.com - October 22 at 2:28 AM
Fate Therapeutics, Inc. (FATE) Receives Consensus Recommendation of "Buy" from BrokeragesFate Therapeutics, Inc. (FATE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 21 at 3:04 AM
Form 4 FATE THERAPEUTICS INC For: Oct 13 Filed by: TAHL CINDY - StreetInsider.comForm 4 FATE THERAPEUTICS INC For: Oct 13 Filed by: TAHL CINDY - StreetInsider.com
www.streetinsider.com - October 18 at 7:57 PM
Zacks Investment Research Downgrades Fate Therapeutics, Inc. (FATE) to HoldZacks Investment Research Downgrades Fate Therapeutics, Inc. (FATE) to Hold
www.americanbankingnews.com - October 17 at 10:58 PM
Cindy Tahl Sells 8,091 Shares of Fate Therapeutics, Inc. (FATE) StockCindy Tahl Sells 8,091 Shares of Fate Therapeutics, Inc. (FATE) Stock
www.americanbankingnews.com - October 17 at 8:18 PM
Fate Therapeutics, Inc. (FATE) Insider Daniel D. Shoemaker Sells 13,225 SharesFate Therapeutics, Inc. (FATE) Insider Daniel D. Shoemaker Sells 13,225 Shares
www.americanbankingnews.com - October 17 at 8:18 PM
ETFs with exposure to Fate Therapeutics, Inc. : October 16, 2017ETFs with exposure to Fate Therapeutics, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 6:56 PM
4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate ... - Benzinga4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate ... - Benzinga
www.benzinga.com - October 13 at 12:23 AM
4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate
finance.yahoo.com - October 12 at 7:22 PM
$1.01 Million in Sales Expected for Fate Therapeutics, Inc. (FATE) This Quarter$1.01 Million in Sales Expected for Fate Therapeutics, Inc. (FATE) This Quarter
www.americanbankingnews.com - October 12 at 10:54 AM
Fate Therapeutics, Inc. (FATE) Coverage Initiated by Analysts at HC WainwrightFate Therapeutics, Inc. (FATE) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - October 12 at 8:02 AM
ETFs with exposure to Fate Therapeutics, Inc. : October 5, 2017ETFs with exposure to Fate Therapeutics, Inc. : October 5, 2017
finance.yahoo.com - October 5 at 5:41 PM
Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 9:49 AM
Fate Therapeutics, Inc. (FATE) Short Interest UpdateFate Therapeutics, Inc. (FATE) Short Interest Update
www.americanbankingnews.com - September 30 at 3:26 AM
Fate Therapeutics (FATE) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowFate Therapeutics (FATE) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 1:11 PM

SEC Filings

Fate Therapeutics (NASDAQ:FATE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fate Therapeutics (NASDAQ FATE) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.